Kyung NAM Pharm

At a glance

Kyung NAM Pharm filed 64 disclosures in the last 12 months, including 9 5% holder, 3 insider and 3 issuance. The most recent key filing was on Oct 12.

Revenue for 2025 was ₩55.9B, down 8% on 2024. It made an operating loss of ₩1.7B. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩33.9B and operating profit of ₩165.3M.

The 2025 annual report lists 238 employees with an average tenure of 8.6 years and average pay of ₩53.7M, #1520 of 2,191 listed companies by average pay. Its 7 directors and auditors were paid ₩36M each on average. It paid no cash dividend for 2025. ㈜빌리언스 and related parties held 27.59% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 3 cut a stake; the largest stake reported was 27.40% on Jun 26.

From the 2025 annual report

Staff: 238 (162 men, 76 women), of whom 23 on fixed-term contracts. Total pay for the year: ₩12.8B. Directors and auditors: 7, paid ₩250M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜빌리언스 holds 17.92%; with 1 related party the group holds 27.59% of common shares at year end.

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports